Trump Ousts FDA Commissioner Makary in Regulatory Overhaul Push

The practical consequences are already visible. Makary had staked out positions on accelerated drug approvals and expanded access pathways, approaches that pharmaceutical and medical device companies had begun building into their go-to-market timelines for 2026 and 2027 launches [1]. An abrupt leade